Bicara Therapeutics Statistics
Total Valuation
BCAX has a market cap or net worth of $1.03 billion. The enterprise value is $741.16 million.
Important Dates
The next estimated earnings date is Monday, April 6, 2026, before market open.
| Earnings Date | Apr 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BCAX has 54.78 million shares outstanding. The number of shares has increased by 1,559.37% in one year.
| Current Share Class | 64.97M |
| Shares Outstanding | 54.78M |
| Shares Change (YoY) | +1,559.37% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 1.93% |
| Owned by Institutions (%) | 63.94% |
| Float | 41.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.55 |
| P/TBV Ratio | 2.56 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.14, with a Debt / Equity ratio of 0.00.
| Current Ratio | 14.14 |
| Quick Ratio | 13.80 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -26.64% and return on invested capital (ROIC) is -19.28%.
| Return on Equity (ROE) | -26.64% |
| Return on Assets (ROA) | -18.59% |
| Return on Invested Capital (ROIC) | -19.28% |
| Return on Capital Employed (ROCE) | -34.96% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.21M |
| Employee Count | 55 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, BCAX has paid $350,000 in taxes.
| Income Tax | 350,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +51.05% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +51.05% |
| 50-Day Moving Average | 17.03 |
| 200-Day Moving Average | 14.53 |
| Relative Strength Index (RSI) | 57.43 |
| Average Volume (20 Days) | 655,360 |
Short Selling Information
The latest short interest is 9.27 million, so 16.92% of the outstanding shares have been sold short.
| Short Interest | 9.27M |
| Short Previous Month | 8.81M |
| Short % of Shares Out | 16.92% |
| Short % of Float | 22.17% |
| Short Ratio (days to cover) | 19.85 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -141.12M |
| Pretax Income | -121.17M |
| Net Income | -121.52M |
| EBITDA | -141.04M |
| EBIT | -141.12M |
| Earnings Per Share (EPS) | -$2.23 |
Full Income Statement Balance Sheet
The company has $290.17 million in cash and $1.98 million in debt, with a net cash position of $288.19 million or $5.26 per share.
| Cash & Cash Equivalents | 290.17M |
| Total Debt | 1.98M |
| Net Cash | 288.19M |
| Net Cash Per Share | $5.26 |
| Equity (Book Value) | 402.78M |
| Book Value Per Share | 7.38 |
| Working Capital | 276.34M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$112.98 million and capital expenditures -$82,000, giving a free cash flow of -$113.06 million.
| Operating Cash Flow | -112.98M |
| Capital Expenditures | -82,000 |
| Depreciation & Amortization | 77,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -113.06M |
| FCF Per Share | -$2.06 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BCAX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1,559.37% |
| Shareholder Yield | -1,559.37% |
| Earnings Yield | -11.81% |
| FCF Yield | -10.98% |
Analyst Forecast
The average price target for BCAX is $25.88, which is 38.25% higher than the current price. The consensus rating is "Buy".
| Price Target | $25.88 |
| Price Target Difference | 38.25% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -35.62% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |